Your browser doesn't support javascript.
loading
Impact of CYP2B6 genotype, tuberculosis therapy, and formulation on efavirenz pharmacokinetics in infants and children under 40 months of age.
Nikanjam, Mina; Tran, Lana; Chadwick, Ellen G; Bwakura-Dangarembizi, Mutsa; Bolton Moore, Carolyn; Samson, Pearl; Spector, Stephen A; Chakhtoura, Nahida; Jean-Philippe, Patrick; Frenkel, Lisa; Zimmer, Bonnie; Benns, Alex; Libous, Jennifer; Capparelli, Edmund V.
Afiliación
  • Nikanjam M; Department of Pediatrics, School of Medicine, University of California San Diego, La Jolla, California.
  • Tran L; Division of Pharmacotherapy and Experimental Therapeutics, School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina.
  • Chadwick EG; Department of Pediatrics, Northwestern University's Feinberg School of Medicine, Chicago, Illinois, USA.
  • Bwakura-Dangarembizi M; Department of Paediatrics and Child Health, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe.
  • Bolton Moore C; Centre for Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama.
  • Samson P; Centre for Infectious Disease Research in Zambia, Lusaka, Zambia.
  • Spector SA; Statistical and Data Management Center (SDMC) Harvard T.H. Chan School of Public Health, Center for Biostatistics in AIDS Research/Frontier Science Foundation, Boston, Massachusetts.
  • Chakhtoura N; Department of Pediatrics, School of Medicine, University of California San Diego, La Jolla, California.
  • Jean-Philippe P; Maternal and Pediatric Infectious Disease Branch (MPIDB), Eunice Kennedy Shriver National Institute for Child Health and Human Development, National Institutes of Health.
  • Frenkel L; Division of AIDS, National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland, USA.
  • Zimmer B; Department of Pediatrics, University of Washington, Seattle, Washington.
  • Benns A; Frontier Science and Technology Research Foundation, Amherst, New York.
  • Libous J; Frontier Science and Technology Research Foundation, Amherst, New York.
  • Capparelli EV; IMPAACT Operations Center, FHI360, Durham, North Carolina, USA.
AIDS ; 36(4): 525-532, 2022 03 15.
Article en En | MEDLINE | ID: mdl-34873089
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Tuberculosis / Infecciones por VIH / Fármacos Anti-VIH Tipo de estudio: Prognostic_studies Límite: Child / Humans / Infant Idioma: En Revista: AIDS Asunto de la revista: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Tuberculosis / Infecciones por VIH / Fármacos Anti-VIH Tipo de estudio: Prognostic_studies Límite: Child / Humans / Infant Idioma: En Revista: AIDS Asunto de la revista: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Año: 2022 Tipo del documento: Article